Genmab — Juni 2017
-
Det må man sige. Måske skulle man gå lidt i Bear i morgen.....der er lang tidtil 18.juli.
-
På FB aktiesnak har jeg fundet en Fierce Biotech artikel, der er lagt på d. 22/6 af Kim Willy Christiansen. Det omhandler den nye chef for FDA, og hvad han vil forbedre. For mig ser det ud til, at Dara kan blive godkendt bredt til al cancer med cd 38 på en gang. Det er noget af en drøm, og afhænger jo af, om han kan gennemføre det.
-
"One example is a cancer where a drug targets a particular molecular subset, regardless of where the tumor arises. We`ll clarify when we can give broad approval to a drug in multiple different kinda of molecularli-similar cancers which are not particular to the tumor being in one specific tissue or organ" Gottlieb said.
-
FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes (1)
Now, in a long-awaited move, U.S. drug regulators will simplify the approval of treatments targeting specific gene mutations that can spur tumors in a variety of organs. The Food and Drug Administration will soon announce a plan to update agency policies and facilitate the approval of critically needed drugs, including so-called “tumor-agnostic” therapies that target cancer-linked DNA, according to FDA Commissioner Scott Gottlieb. “The most tangible way we’re going to reduce health-care costs is by finding better treatments for a lot of costly diseases,” Gottlieb told the Senate panel responsible for overseeing the agency’s budget on Tuesday.
Yahoo Finance (sg.finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind